2017 - Reference list of hepatitis publications of the VHPB board members
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients with HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. |
Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. |
Clin Gastroenterol Hepatol. 2017 Sep 22. pii: S1542-3565(17)31162-X. doi: 10.1016/j.cgh.2017.09.027. |
Sofosbuvir-Daclatasvir-Simeprevir plus Ribavirin in Direct-Acting Antiviral-Experienced Hepatitis C Patients. |
Hezode, C., S. Fourati, S. Chevaliez, G. Scoazec, A. Soulier, A. Varaut, M. Francois, I. Ruiz, F. Roudot-Thoraval, A. Mallat and J. M. Pawlotsky. |
Clin Infect Dis. 2017 |
Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers' vaccination since 1999 and low clinical incidence in all age groups. |
Manor Y, Lewis M, Ram D, Daudi N, Mor O, Savion M, Kra-Oz Z, Shemer Avni Y, Sheffer R, Shouval D, Mendelson E. |
J Infect Dis. 2016 Dec 23. pii: jiw611. doi: 10.1093/infdis/jiw611. |
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. |
Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU). |
Lancet Gastroenterol Hepatol. 2017 Oct 3. pii: S2468-1253(17)30284-4. doi: 10.1016/S2468-1253(17)30284-4. |
Late presentation of chronic viral hepatitis for medical care: a consensus definition. |
Mauss, S., S. Pol, M. Buti, E. Duffell, C. Gore, J. V. Lazarus, H. L. der Grient, J. Lundgren, A. Mozalevskis, D. Raben, E. Schatz, S. Wiktor and J. K. Rockstroh. |
BMC Med. 2017; 15(1): 92. |
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. |
Nahon, P., V. Bourcier, R. Layese, E. Audureau, C. Cagnot, P. Marcellin, D. Guyader, H. Fontaine, D. Larrey, V. De Ledinghen, D. Ouzan, F. Zoulim, D. Roulot, A. Tran, J. P. Bronowicki, J. P. Zarski, V. Leroy, G. Riachi, P. Cales, J. M. Peron, L. Alric, M. Bourliere, P. Mathurin, S. Dharancy, J. F. Blanc, A. Abergel, L. Serfaty, A. Mallat, J. D. Grange, P. Attali, Y. Bacq, C. Wartelle, T. Dao, Y. Benhamou, C. Pilette, C. Silvain, C. Christidis, D. Capron, B. Bernard-Chabert, D. Zucman, V. Di Martino, V. Thibaut, D. Salmon, M. Ziol, A. Sutton, S. Pol and F. Roudot-Thoraval. |
Gastroenterology. 2017; 152(1): 142-156.e142. |
The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016. |
Nasrullah, M., D. Sergeenko, L. Gvinjilia, A. Gamkrelidze, T. Tsertsvadze, M. Butsashvili, D. Metreveli, L. Sharvadze, M. Alkhazashvili, S. Shadaker, J. W. Ward, J. Morgan and F. Averhoff. |
MMWR Morb Mortal Wkly Rep 2017; 66(29): 773-776. |
Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. |
Notarpaolo, A., R. Layese, P. Magistri, M. Gambato, M. Colledan, G. Magini, L. Miglioresi, A. Vitale, G. Vennarecci, C. D. Ambrosio, P. Burra, F. Di Benedetto, S. Fagiuoli, M. Colasanti, G. Maria Ettorre, A. Andreoli, U. Cillo, A. Laurent, S. Katsahian, E. Audureau, F. Roudot-Thoraval and C. Duvoux. |
J Hepatol. 2017; 66(3): 552-559. |
Persistence of immunity 18-19 years after vaccination against hepatitis B in 2 cohorts of vaccinees primed as infants or as adolescents in Italy. |
Romano, L., C. Galli, C. Tagliacarne, M. E. Tosti, C. Velati, L. Fomiatti, M. Chironna, R. C. Coppola, M. Cuccia, R. Mangione, F. Marrone, F. S. Negrone, A. Parlato, C. M. Zotti, A. Mele and A. R. Zanetti. |
Hum Vaccin Immunother. 2017; 13(5): 981-985. |
Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. |
Stone, J., N. K. Martin, M. Hickman, S. J. Hutchinson, E. Aspinall, A. Taylor, A. Munro, K. Dunleavy, E. Peters, P. Bramley, P. C. Hayes, D. J. Goldberg and P. Vickerman. |
Addiction. 2017 |
Seroepidemiology of HEV and HAV in two populations with different socio-economic levels and hygienic/sanitary conditions. |
Zuin M, Caserta C, Romanò L, Mele A, Zanetti A, Cannatelli R, Giorgini A, Tagliacarne C, Amante A, Marcucci F, Battezzati PM. |
Eur J Clin Microbiol Infect Dis 2017; 36: 479-485. |
Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in Italy. |
Zanetti, A., M. G. Desole, L. Romano, A. d'Alessandro, M. Conversano, G. Ferrera, M. G. Panico, A. Tomasi, G. Zoppi, M. Zuliani, S. Thomas, B. Soubeyrand, C. Eymin and S. Lockhart. |
Vaccine 2017; 35(32): 4034-4040. |
Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review.
Stuurman AL, Marano C, Bunge EM, De Moerlooze L, Shouval D.
Hum Vaccin Immunother. 2017 Mar 4;13(3):724-736. Review.
Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review.
Carrillo-Santisteve P, Tavoschi L, Severi E, Bonfigli S, Edelstein M, Byström E, Lopalco P; ECDC HAV Expert Panel.
Lancet Infect Dis. 2017 Oct;17(10):e306-e319. doi: 10.1016/S1473-3099(17)30392-4. Epub 2017 Jun 20.
Third edition of the Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV. Matičič M. Germs. 2017 Jun 1;7(2):60. doi: 10.18683/germs.2017.1109. eCollection 2017 Jun.
Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses. Lazarus JV, Safreed-Harmon K, Stumo SR, Jauffret-Roustide M, Maticic M, Reic T, Schatz E, Tallada J, Harris M; Hep-CORE Study Group. Int J Drug Policy. 2017 Sep;47:47-50. doi: 10.1016/j.drugpo.2017.05.054. Epub 2017 Jul 6.
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ.
Clin Gastroenterol Hepatol. 2018 Mar;16(3):417-426. doi: 10.1016/j.cgh.2017.09.027. Epub 2017 Sep 22.
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.
Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).
Lancet Gastroenterol Hepatol. 2018 Feb;3(2):125-133. doi: 10.1016/S2468-1253(17)30284-4. Epub 2017 Oct 3
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.
Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Zucman D, Di Martino V, Bagnis CI, Ziol M, Sutton A, Letouze E, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir group.
Am Heart J. 2018 Apr;198:4-17. doi: 10.1016/j.ahj.2017.10.024. Epub 2017 Nov 7.
Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries.
Leblebicioglu H, Arends JE, Ozaras R, Corti G, Santos L, Boesecke C, Ustianowski A, Duberg AS, Ruta S, Salkic NN, Husa P, Lazarevic I, Pineda JA, Pshenichnaya NY, Tsertswadze T, Matičič M, Puca E, Abuova G, Gervain J, Bayramli R, Ahmeti S, Koulentaki M, Kilani B, Vince A, Negro F, Sunbul M, Salmon D; ESGHV (part of ESCMID).
Antiviral Res. 2018 Feb;150:9-14. doi: 10.1016/j.antiviral.2017.12.001. Epub 2017 Dec 5.
Mortality Associated with Hepatobiliary Disease in Portugal between 2006 and 2012.
da Rocha MC, Marinho RT, Rodrigues T.
GE Port J Gastroenterol. 2018 Apr;25(3):123-131. doi: 10.1159/000484868. Epub 2017 Dec 6.
Is hepatitis B vaccination performed at infant and adolescent age able to provide long-term immunological memory? An observational study on healthcare students and workers in Florence, Italy.
Bini C, Grazzini M, Chellini M, Mucci N, Arcangeli G, Tiscione E, Bonanni P.
Hum Vaccin Immunother. 2018 Feb 1;14(2):450-455. doi: 10.1080/21645515.2017.1398297. Epub 2017 Dec 19.
Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.
Fourati S, Guedj J, Chevaliez S, Nguyen THT, Roudot-Thoraval F, Ruiz I, Soulier A, Scoazec G, Varaut A, Poiteau L, Francois M, Mallat A, Hézode C, Pawlotsky JM.
Aliment Pharmacol Ther. 2018 Mar;47(5):665-673. doi: 10.1111/apt.14478. Epub 2017 Dec 22.